Survival of Hypercapnic Patients with COPD and Obesity Hypoventilation Syndrome Treated with High Intensity Non Invasive Ventilation in the Daily Routine Care



Home ventilation is an effective treatment option for obesity hypoventilation syndrome (OHS). This therapy is still controversial for stable chronic obstructive pulmonary disease (COPD). A recent study showed reduced mortality for COPD patients receiving home ventilation with high inflation pressures and back-up respiratory rates [so called High Intensity non-invasive ventilation (NIV)].


The purpose of this study is whether High Intensity NIV applied in the routine care of COPD and OHS patients can lead to CO2 reduction and survival data comparable to data from controlled studies.


In this prospective non interventional study fifty-one patients with COPD (FEV1 0.95l, corr. 32.8%) and 34 patients with OHS (VC 1.74l, corr. 50.7%) with chronic hypercapnic respiratory failure, who were treated with NIV were followed up for four years.


Elevated CO2 values before NIV in COPD patients (8.6kPa), and in OHS patients (8.3kPa), could be lowered significantly to the upper normal range (COPD: 5.9kPa; OHS: 5.85kPa). The one-, two-, and three-year survival rates for COPD patients were 83%, 73%, and 55%, respectively. The one-, two-, and three-year survival rates for OHS patients were 85%, 72%, and 68%, respectively.


High intensity NIV within routine care is effective in reducing blood CO2 levels in COPD- and in OHS- related chronic respiratory insufficiency. The survival rates obtained here are comparable to data from controlled clinical trials on COPD.

Keywords: Chronic Obstructive Pulmonary Disease, Non-invasive ventilation, Routine care, Hypercapnia, Ventilatory insufficiency, Prognosis, Home ventilation, Routine care.


Chronic respiratory failure, in severe COPD, leads to a deterioration of the quality of life and a significant worsening of prognosis [1]. While the value of non-invasive ventilation, in cases of acute COPD exacerbation, has long been undisputed [2] , home ventilation for chronic respiratory failure, caused by COPD, is not yet established. This is due to controversy in the literature. Compared with other diseases, such as obesity hypoventilation syndrome (OHS), the clinical and prognostic effects of non-invasive ventilation (NIV), in chronic respiratory failure due to COPD, are not always demonstrable [3, 4]. In studies showing benefits to prognosis and the quality of life, or a reduced hospitalisation rate in COPD, the patients were predominantly severely hypercapnic and the treatment was carried out with high pressures and high ventilation rates (so called “High Intensity NIV”) [5-10]. In studies showing no benefit of home ventilation therapy in stable COPD, the patients were either less hypercapnic, the ventilation pressures lower, or they were acute ventilatory decompensated patients who were switched to home ventilation [11-13] after acute care ventilation. Continuing artificial ventilation therapy as home ventilation, even when carried out at high pressures and high frequencies, has not shown any prognostic effect in acute respiratory insufficient COPD patients [13] . A recent study by Koehnlein et al. 2014 [5] showed that “High Intensity NIV” had a significant influence on mortality in a controlled trial in severely hypercapnic, stable COPD patients. Fourteen days of intense patient contact were a special feature of this study’s design. On the other hand, in chronic respiratory/ventilatory failure due to OHS, the prognostic value of non-invasive ventilation is undisputed [14-16] . In contrast to COPD, this disease is not characterised by frequent exacerbations. In an earlier study by Janssens et al. in 2003 [4] it was shown, for example, that in OHS, in contrast to COPD, home ventilation led to a significant reduction of hypercapnia and improved survival.

The purpose of this study is whether High Intensity NIV applied in the routine care of COPD and OHS patients can lead to CO2 reduction and survival data comparable to data from controlled studies. The second question is whether high intensity NIV in COPD is comparable with OHS with respect to the reduction of hypercapnia and survival.


Study Design in- and Exclusion Criteria

This was a prospective non interventional single centre study performed on a centre for home ventilation in a hospital with approximately 500 beds. The recruitment period was from January to December 2011. The median follow up period was four years. The study has been approved by the local ethics committee prior to the start of the study.

We recruited all inpatients, with stable COPD and OHS, who were adjusted to NIV due to chronic respiratory insufficiency on a specialized normal ward. Patients were admitted because of daytime hypercapnia. The recruitment took place before discharge with intermittent non-invasive home ventilation. COPD was diagnosed according to the international guidelines (GOLD), based on anamnestic information, the clinical examination, and pulmonary function (post-bronchodilator- FEV1/FVC < 70%). OHS was diagnosed according to the current common definitions, based on a BMI > 30kg/m2, detection of chronic daytime hypercapnia (pCO2 > 6.7kPa, pH > 7.35), and characteristic symptoms [14, 15, 17]. Patients with anamnestic, clinical or Para clinical indications of exacerbation, or respiratory acidosis, were excluded. Likewise, patients with indications of decompensated left- or right-ventricular heart failure, or other conditions that could lead to chronic respiratory failure, were not enrolled in this study (Table 1).

Table 1.
In- and exclusion criteria.
Inclusion Criteria Exclusion Criteria
Daytime pCO2 > 7,0kPa, ph > 7,35
FEV1/FVC < 80%
Established diagnosis of COPD according to GOLD
Stable on inhaled medication
Worsened dyspnoea, cough, increased sputum production two weeks before entry oft the study
Clinical signs of an exacerbation [22]
Any other cause for hypercapnia
Decompensated cor pulmonale
Systemic corticosteroids
Obesity Hypoventilation
Daytime pCO2 > 7,0kPa, ph > 7,35
FVC < 70%
BMI > 30kg/m2
FEV1/FVC < 80%
Any other cause for hypercapnia
Decompensated cor pulmonale

Arterial blood gas analysis (ABG), before NIV, was carried out in the morning, at rest, in spontaneously breathing, seated patients using blood from the hyperaemic earlobe. ABG prior to discharge was carried out, two hours after NIV, in spontaneously breathing patients. Obese patients with a relative FEV1 of less than 0.7 were not classified as OHS patients. Six-minute walk tests were carried out using Guyatt’s method.

Schedule of Therapy Initiation

After appropriate instruction patients were gradually familiarised (twice daily) with the home ventilation parameters, as well as, the duration of the ventilation intervals. Only conventional mouth-nose masks and a tubing system with valve control were used. The ventilation device used was a VSIII, (Saime SA, France) and the mainly used ventilation mode applied was APCV (assisted pressure controlled ventilation). When APCV was not achievable, pressure support ventilation was accepted if normocapnia could be documented. The inspiratory pressure was chosen such that the patient did not experience any “air hunger” during inspiration and a tidal volume of, at least, 800ml was reached. The goal was a minimum Pinsp >/= 20 cm H2O. PEEP was applied in all OHS patients and in COPD patients with indications of obstructed exhalation (due to instability of the upper airways). In each case, the lowest possible PEEP was used. The algorithm for selecting the optimum PEEP worked by escalating/increasing PEEP until unhindered, even exhalation, and comfortable inhalation triggering for the patient, became possible. The ventilation rate was set at two breaths/min above the spontaneous respiratory rate, of the patient, for 80% of breaths. The duration of ventilation was gradually extended to at least 12h/d. The objective was to reach normocapnia during spontaneous breathing, as well as, acceptance of the therapy. If hypoxaemia was still detectable during effective ventilation, oxygen supplementation was provided in accordance with the recommendations for LTOT (GOLD). Patients were discharged when normocapnia was achieved within the period of spontaneous breathing, or when the pCO2 has decreased by at least 1kPa, and a steady state of spontaneous breathing pCO2 values was reached. A further requirement for discharge with NIV was the ability to safely handle the ventilation device, as well as, the willingness of the patient to apply the therapy to the prescribed extent. Patients who rejected this form of therapy during the titration phase, or who could not use it independently were not included in this study.

Follow-up Examinations

Standardised, inpatient follow-up examinations were carried out, initially, four weeks after setting up NIV, then 12 weeks after the first check-up examination, and subsequently in six-monthly intervals. If no modifications in the ventilation therapy were necessary within the first year after adjustment, check-up examinations were carried out annually. During follow-up examinations complications and ventilatory effectiveness were reviewed. This included nocturnal oximetry, ABG during NIV, while spontaneously breathing at rest and under physical challenge. For these tests, patients were hospitalised for one night. Survival data were obtained in a two-step process. In the first step, treatment data of the ventilation device were collected by the device provider. Information regarding discontinuation of treatment and survival status were recorded for all patients within the four-year study period. In cases of treatment discontinuation, the reason for discontinuation or, where applicable, the date of death was medically validated in the second step. The last control examination, within the four-year study period, was recorded as the last point of contact. The average daily device use duration was calculated from the total hours of ventilation recorded in the device memory divided by the number of usage days in the first year, or by the total usage period.

Data Management and Statistics

Patient data and ventilation specific data were entered after enrolment into a database and continuously updated over the course of the study. The number of ventilation hours was read out and recorded from the ventilation device by the device provider after 12 months of ventilation, or after discontinuation/death of the patient. Plausibility checks were performed at an individual case level, as well as, at the database level, and if necessary, corrections were made. Implausible data that were impossible to clarify were recorded as missing. Continuous data were reported as mean and standard error as the sample data were normally distributed. Categorical data were recorded as n and %. Statistical tests were performed using t-tests for group differences. Survival was documented using the univariate Kaplan-Meier-analysis survival analysis. Statistical analyses were performed using the statistics package SPSS 17.0 (IBM, Germany).


1. Patient Characteristics

The defined patient groups have characteristic anthropometric and pulmonary function data. Pulmonary function analysis in COPD patients showed a severe degree of obstructive respiratory disorder, as well as, severe distension of the lung. The median BMI shows that the patients were predominantly obese; therefore, this patient cohort was phenotypically characterised as predominantly bronchitic. OHS patients, with a vital capacity of 50.7%, characteristically have considerable restrictive functional impairment (Table 2). The extent of hypercapnia (COPD 8.6kPa; OHS 8.3kPa) indicates severely hypercapnic patients with respiratory insufficiency.

Table 2.
Patient characteristics.
mean SE mean SE
Age at enrolment 66.9 1.3 65.4 1.8
Proportion of males (n; %) 32 63% 17 50%
BMI in kg/m2 34.6 1.4 45.4 1.4
6 MWT in m 206.8 17.9 190.8 24.8
FEV1 in l 1.1 0.1 1.4 0.1
FEV1 in % 42.7 2.5 54.8 3.0
rel. FEV1 0.6 0.0 0.8 0.0
VC in l 2.0 0.1 1.8 0.1
VC in % 55.1 2.1 55.2 2.9
RV in l 4.3 0.3 2.5 0.2
RV in % 191.2 12.7 114.9 7.6
ITGV in l 4.9 0.3 2.9 0.2
ITGV in % 155.5 8.4 97.2 6.9
6 MWT: 6-minute walk test distance, BMI: Body Mass Index, lung function parameters: please refer to abbreviations list. Shown are arithmetic means and standard errors (SE), unless indicated otherwise.

2. Ventilation Effectiveness

Ventilation parameters are shown in Table 3 below. High inspiration and high effective pressures (Pinsp-PEEP) were achieved. Inspiration pressures and ventilation rates (VR) were similar between COPD and OHS patients (with PInsp of 22 vs. 22cm H2O and VR of 15.8/min vs. 15.3/min). Ventilation parameters differed in PEEP values (COPD: 2.3 cm H2O; OHS: 5.3 cm H2O). The low PEEP and the high proportion of patients with a PEEP of zero result from the PEEP titration scheme applied here and the control of exhalation through a valve system.

Table 3.
Ventilation parameters in COPD and OHS.
P Values
Number of patients with APCV, n (%) 49 96.1% 28 82.3% 0,340
Pinsp in cm H2O 22 3.7 22 3.9 0,43
PEEP in cm H2O 2.3 2.5 5.3 2.7 0,18
Number of patients with PEEP = 0, n (%) 21 41% 0 0% 0,026
Effective pressure in cm H2O 18.5 0.74 16.9 0.88 0,095
Ventilation rate in breaths/min 15.8 3.3 15.3 2.9 0,48
Prescribed duration of ventilation in h/d 11.8 2.4 11.1 1.9 0,51
Number of patients rejecting therapy, n (%)* 9 18% 7 21% 0,071
Average device usage in h/d * 5.6 4.4 5.2 3.2 0,17
Number of patients with pCO2 < 5.7kPa with NIV, n (%) 36 70.6% 21 61.8% 0,11
Shown are arithmetic means and standard errors, unless indicated otherwise. Data were collected at discharge after initiation of NIV unless different stated. Ventilation parameters are set parameters * data achieved after 12 month NIV Average device usage: calculated mean of daily increase of use-hours. p-Values: non parametric test (Mann & Whitney) for independent samples.

On average patients were discharged with a prescription of 12h/d of intermittent assisted ventilation. The prescribed ventilation durations did not differ significantly between COPD and OHS patients.

The effectiveness of ventilation therapy was comparable between the two groups according to the pCO2 values measured at discharge (Table 4). The clearly increased values before ventilation in COPD (8.6kPa), as well as in OHS (8.3kPa), could be lowered significantly to the upper normal range (COPD: to 5.9kPa; OHS: to 5.85kPa). Normocapnia was achieved under ventilation therapy in COPD in 70.6% of cases, and in OHS in 61.8% of cases. With home ventilation COPD patients achieved a CO2 reduction of 1.7kPa (corresponding to 19.8% of the initial value). OHS patients achieved a CO2 reduction of 1.5kPa (corresponding to 18.1% of the initial value). The extent of metabolic hypercapnia compensation, as measured by HCO3 and BE values, could be reduced towards normal, in both groups, but not to within the normal range. The BE and bicarbonate values at discharge were 6 and 30 mmol/l, in COPD patients and 4.5 and 29.4mmol/l, in OHS patients. Overall, we found that under ventilation the ventilation specific ABG parameters (pCO2, BE, HCO3) normalised slightly more in OHS patients than in COPD patients. Prior to ventilation OHS patients had a pO2 of 7.55 kPa and oxygen saturation (SO2) of 86% more hypoxic than COPD patients who had an average pO2 of 8.25 kPa and SO2 value of 90%. The proportion of patients that had to receive long-term oxygen supplementation, in addition to ventilation, was the same in both groups. Sufficient oxygenation was achieved in both groups. The physical capacity of COPD and OHS patients, as measured by the 6-minute walking distance test, was significantly limited. During the course of inpatient treatment, the walking distance of both groups significantly increased from 193m to 271m in COPD patients, and from 192m to 238m in OHS patients. The increase in walking distance of COPD patients was significantly higher (78m) than OHS patients (42m).

Table 4.
Ventilation effectiveness according to blood gas analysis parameters in COPD and OHS.
Before NIV With NIV Diff. 95% CI of the difference
mean SE mean SE mean lower upper p
pH 7.36 0.06 7.45 0.04 -0.09 -0.11 -0.07 0
pCO2 8.7 1.5 5.8 0.8 2.83 2.34 3.29 0
pO2 8.0 1.8 10.2 1.4 -2.25 -2.94 -1.56 0
HCO3 32.4 6.0 30.2 3.7 2.24 0.67 3.80 0.006
BE 8.6 5.2 5.8 3.0 2.78 1.30 4.26 0
SO2 87.5 8.2 95.7 2.6 -8.2 -10.64 -5.75 0
6-MWT 206.8 110.4 267.0 108.4 60.2 81.7 38.8 0
pH 7.37 0.06 7.45 0.05 -0.08 -0.10 -0.06 0
pCO2 8.5 1.2 5.9 0.8 2.55 2.12 2.98 0
pO2 7.6 1.3 10.0 1.7 -2.37 -2.99 -1.75 0
HCO3 32.7 4.9 30.0 4.0 2.65 0.98 4.32 0.003
BE 8.5 4.1 5.1 2.7 3.43 2.02 4.84 0
SO2 86.7 5.4 95.1 2.6 -8.34 -10.40 -6.35 0
6-MWT 190.8 124.0 259.0 137.4 65 93.7 36.2 0
Blood gas analysis at rest, spontaneous breathing. Before NIV: Before initiation of ventilation; with NIV: before discharge with ventilation. Values as mean, standard deviation, and difference: before NIV – with NIV; 6-MWT walk distance: with NIV – before NIV. p: significance level, two-sided, (t-test for dependent samples).

3. Survival Analysis

The one-, two-, three-, and four-year survival rates (SR) for artificially ventilated COPD patients were 83%, 73%, 55%, and 26%, respectively. One- and two-year survival rates of OHS patients were identical at 85% and 72%, three- and four-year survival rate was 68%, which was better than that of COPD patients (Table 5 and Fig. 1).

Table 5.
Survival of COPD and OHS patients: Univariate Analysis - Kaplan-Meier.
% SE in % % SE in %
1 year survival rate 83.3 5.4 85.1 6.2
2 year survival rate 72.8 6.8 72.1 8.0
3 year survival rate 55.2 8.1 68.3 8.4
Median survival time 47.3 Mo. 8.3 Mo. Not reached
Fig. (1). Survival of COPD and OHS patients: Univariate Analysis Kaplan-Meier.


Discussion of the Ventilation Settings and Blood Gas Analysis

In this study, stable COPD and OHS patients were treated with home artificial ventilation at high inspiration pressures and high ventilation rates. The bicarbonate and the BE values in COPD and OHS patients (COPD 32.9mmol/l and 8; OHS 31.7mmol/l and 7.5) indicate, in addition to a normal pH value, that these patients have chronic respiratory insufficiency. The ventilator settings corresponded to ventilation parameters that were used in earlier studies of COPD and OHS patients, who used home ventilation with the aim of reducing hypercapnia due to respiratory insufficiency in chronically ill patients [5, 9, 10, 18, 19]. Patients were artificially ventilated with high effective pressures of 18cm H2O (COPD), and 17cm H2O (OHS). The difference between COPD and OHS patients was due to the need for a higher PEEP in the OHS group. PEEP was applied in all OHS patients and in COPD patients with indications of obstructed exhalation (due to instability of the upper airways). In each case, the lowest possible PEEP was used. The algorithm for selecting the optimum PEEP worked by escalating/increasing PEEP until unhindered, even exhalation, and comfortable inhalation triggering for the patient, became possible. This achieved a relatively low PEEP in OHS patients, and a PEEP of 0 cm H2O in 41% of COPD patients, which in our view promotes compliance.

Within the first year of this study, discontinuation rates of 18% and 21% were documented in COPD and OHS patients, respectively. These discontinuation rates are to be regarded as high; however, they were not primarily caused by a lack of acceptance of the high ventilation pressures used, but rather predominantly by a reduced disease perception and a lack of willingness to carry out an elaborate and costly therapy on their own. With this therapy, effective, short-term CO2 reduction was achieved in both groups. The improvement of ventilation specific parameters (pCO2, BE, HCO3) was comparable in both groups. Thereby, we can substantiate that in COPD patients with chronic respiratory failure under home ventilation, with high ventilation pressures, a recompensation of the respiratory insufficiency can be achieved that is similar to OHS patients.

Discussion of Survival Rates

The one-, two-, and three-year SR for artificially ventilated COPD patients were 83%, 73%, and 55%, respectively. The one-year SR of COPD patients, in our study, is comparable with data from Köhnlein et al. 2014 [5] (one-year SR 88%) who used similar ventilation parameters, but a slightly lower intensive follow-up regimen. However, patients in our study, were older (median age 68.7 vs. 62.2 years) and physically more limited (6-minute walk distance: 196 vs. 226m). Although the patients we analysed were more severely hypercapnic compared to Köhnlein et al.’s [5] study (pCO2 8.6kPa vs. 7.8kPa), we found a similar reduction in CO2 of 1.7kPa (corresponding to 19.8% of the initial value) after initiation of artificial ventilation. In a study by Borel et al. 2014 [10], the three-year SR for artificially ventilated COPD patients was approximately 40% (mortality rate 45.5% in 44.7 months) and, therefore, lower than in this study. The patients were approximately of the same age (68.7 vs. 68 years), but hypercapnia was lower in Borel et al. [10] at 48.5mm Hg (7.3kPa). However, in the aforementioned study, 50% of patients were adjusted to home ventilation after acute care ventilation. In our study, we excluded patients who received acute care ventilation. Apart from the proportion of patients, receiving acute care ventilation it was notable that the effective ventilation pressure (Pinsp – PEEP) in Borel et al. [10] was significantly lower at 11cm H2O compared to our study (19.7cm H2O). In a study on chronically respiratory insufficient patients, by McEvoy et al. 2009 [6], a lower 3-year SR (approximately 48%) under NIV can be inferred. Compared to our study the patients were of the same age; however less obese (BMI 25.4 vs. 32.4kg/m2), and had slightly lower FEV1 values (0.55l, corr. 23.1% vs. 0.95l, corr. 32,8%). The initial pCO2 was 6.9kPa, and, therefore, lower than in the patients presented here. It is remarkable that in this study, as well, the effective ventilation pressure was only 7.8cm H2O, and that the average duration of ventilation was 4.5h/d. We assume that in the studies of McEvoy et al. [6] and Borel et al. [10] less hypercapnic patients were examined, and that the ventilation intensities (with respect to the ventilation pressure and duration of ventilation) were lower than in our study. Thus, it can be concluded that in severely hypercapnic COPD patients, ventilation therapy with high pressures and rates appears to be associated with improved survival.

In the OHS patients of our study, ventilation therapy also leads to a significant reduction of pCO2 values from 8.3 to 5.8kPa. Therefore, we achieved greater CO2 reduction (-4kPa) compared to a recent study by Masa et al. 2015 [20] (-1kPa) that reported their CO2 reduction as clinically relevant. In comparison with a similar study by Ojeda et al. in 2015 [21], the 3-year survival rates for OHS patients presented here are approximately 15% worse. In this aforementioned study, a 3-year SR of 83% was achieved. Therapy compliance and average daily use duration were better in the Spanish study (5.7h/d vs. 5.3h/d) compared to our study. To what extent a longer use duration, or other disease characteristics (degree of functional impairment, age, or extent of hypercapnia) contribute to prognosis, ultimately remains unresolved. When comparing SRs of COPD patients with SRs of OHS patients in our study it becomes evident that one- and two-year survival of COPD patients is approximately the same as in OHS patients.

In our view, the positive prognostic effects of intensive therapy in COPD patients are associated with a compliance that can be rated as good, given a discontinuation rate of 18% within four years in COPD patients (compared to 21% in OHS patients), and an average daily use duration of 5.6h/d (5.2h/d in OHS patients) within the first year. However, this can be regarded as coincidental due to the low number of cases with analysable patient data after four years. In a large randomised study by Köhnlein et al. 2014 [5] using “High Intensity NIV” and providing 14 days of intensive contact with patients, a slightly higher average daily use duration of 5.9h/d and a lower discontinuation rate of 9.1% was achieved. Thus, we achieved similar compliance and a similar outcome using “High Intensity NIV”, however with significantly lower patient care expenditure. Our results on survival, depending on ventilation duration, indicate that consistent home ventilation, i.e. effective and long-term relief of the insufficient respiratory musculature, is prognostically relevant.

Limitation of this Study

  1. The effectiveness of ventilation therapy was documented by the extent of CO2 reduction under spontaneous breathing at the end of the inpatient stay at which ventilation parameters were set. CO2 follow-up examinations were carried out to verify ventilation effectiveness, but were not included in this study. Since the treatment protocol made provisions for intervention, under any circumstances, in case of progressive hypercapnia during the course of treatment, in our view, the influence of different CO2 concentrations over the course of treatment was considered irrelevant to the questions presented. Device-usage data were recorded only during the first year.
  2. Obstructive sleep apnoea is common in patients with obese COPD. Most of COPD patients in this study were obese (mean BMI was 34.6). Some of them may have obstructive sleep apnoea. We know that approximately 90% of patients with OHS also have obstructive sleep apnoea. There may was a certain bias because of the influence of treated sleep apnoea on adherence or survival.
  3. Adherence was recorded only during the first year of home ventilation. Clinical experience with our patient cohort regarding therapy acceptance has shown that compliance changes within the first 6 – 9 months. After that only minor changes in compliance were observed.


In summary, our data show that “High Intensity NIV” in chronically hypercapnic COPD patients was efficient in routine care (with respect to CO2 reduction), and led to prognostically relevant survival rates that are similar to those reported earlier in randomised studies.

Furthermore, it was demonstrated that high intensity NIV in stable COPD leads to an effective relief of the respiratory musculature as measured by CO2 concentration is feasible and efficient even outside controlled clinical trials.

Under the “High Intensity NIV” regimen that we describe here, a significant, and in comparison with OHS patients, equally strong reduction of pCO2 values was achieved in COPD patients. Our data showed that with the selected ventilation procedure it is possible to achieve a CO2 reduction in COPD patients that is similar to OHS patients.


COPD  = chronic obstructive pulmonary disease
OHS  = obesity hypoventilation syndrome
NIV  = non invasive ventilation
CO2  = carbon dioxide
O2  = oxigene
FEV1  = forced expiratory volume in one / 1 second
VC  = vital capacity
FVC  = forced vital capacity
ABG  = arterial blood gasses
APCV  = assisted pressure controlled ventilation
pinsp  = inspiratory pressure
PEEP  = positive endexspirarory pressure
h  = hours
d  = day
pCO2  = carbondioxide pressure
pO2  = oxygene pressure
BMI  = body mass index
BE  = base excess
HCO3  = hydrogene bicarbonate
6 MWT  = six minute walking test
RV  = residual volume
ITGV  = intrathoracic gass volume
SO2  = oxygene saturation
SE  = standard error
CI  = confidence intervall
SR  = survival rate


Not applicable.


No Animals/Humans were used for studies that are base of this research.


Not applicable.


The author (editor) declares no conflict of interest, financial or otherwise.


We would like to thank Mr. T. Heyke and Mr. J. Baacke at Vital Aire GmbH, Leipzig, for technical assistance and logistical support with recording device usage data. Special thanks to all established GPs and Consultants in the region for supplying essential progress data.


Foucher P, Baudouin N, Merati M, et al. Relative survival analysis of 252 patients with COPD receiving long-term oxygen therapy. Chest J 1998; 113(6): 1580-7. Available from:
Confalonieri M, Parigi P, Scartabellati A, et al. Non invasive mechanical ventilation improves the immediate and long - term outcome of COPD patients with acute respiratory failure. Eur Respir J 1996; 9(3): 422-30.
Casanova C, Celli BR, Tost L, et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest 2000; 118(6): 1582-90.
Janssens J-P, Derivaz S, Breitenstein E, et al. Changing patterns in long-term noninvasive ventilation: a 7-year prospective study in the Geneva Lake area. Chest 2003; 123(1): 67-79.
Koehnlein T, Windisch W, Koehler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. lancet Respir Med 2014; 2600(14): 698-705.
McEvoy RD, Pierce RJ, Hillman D, et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax 2009; 64(7): 561-6.
Budweiser S, Hitzl AP, Jörres RA, Schmidbauer K, Heinemann F, Pfeifer M. Health-related quality of life and long-term prognosis in chronic hypercapnic respiratory failure: a prospective survival analysis. Respir Res 2007; 8: 92.
Blankenburg T, Roloff D, Schädlich S, Crieé CP, Schütte W. Rekompensation von schwerem hyperkapnischem Versagen bei Patienten mit COPD unter 4 Wochen intermittierender nicht invasiver Heimbeatmung. Pneumologie 2008; 62(3): 126-31.
Windisch W. Impact of home mechanical ventilation on health-related quality of life. Eur Respir J 2008; 32(5): 1328-36.
Borel J-C, Pepin J-L, Pison C, et al. Long-term adherence with non-invasive ventilation improves prognosis in obese COPD patients. Respirology 2014; 19(6): 857-65.
Clini E, Sturani C, Rossi A, et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002; 20(3): 529-38.
Casanova C, Celli BR, Tost L, et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest 2000; 118(6): 1582-90.
Struik FM, Sprooten RT, Kerstjens HA, et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax 2014; 69(9): 826-34.
Pépin JL, Borel JC, Janssens JP. Obesity hypoventilation syndrome: an underdiagnosed and undertreated condition. Am J Respir Crit Care Med 2012; 186(12): 1205-7.
Mokhlesi B. Obesity hypoventilation syndrome: a state-of-the-art review. Respir Care 2010; 55(10): 1347-62.
Published S, German T, Association M, Support V. Nichtinvasive und invasive Beatmung als Therapie der chronischen respiratorischen Insuffizienz S2-Leitlinie herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizine. In: V. 2010; pp. 207-40.
Randerath WJ, Stieglitz S, Galetke W, Laumanns C, Duchna H-W, Schäfer T. Pathophysiology of the obesity hypoventilation syndrome. Pneumologie 2008; 62(7): 398-403.
Storre JH, Matrosovich E, Ekkernkamp E, et al. Home mechanical ventilation for COPD: high-intensity versus target volume noninvasive ventilation. Respir Care 2014; 59(9): 1389-97.
Pépin J-L, Borel J-C, Janssens J-P. Obesity hypoventilation syndrome: an underdiagnosed and undertreated condition. Am J Respir Crit Care Med 2012; 186(12): 1205-7.
Masa JF, Corral J, Alonso ML, et al. Efficacy of different treatment alternatives for obesity hypoventilation syndrome: Pickwick study. Am J Respir Crit Care Med 2015; 192(1): 86-95.
Ojeda Castillejo E, de Lucas Ramos P, López Martin S, et al. Noninvasive mechanical ventilation in patients with obesity hypoventilation syndrome. Long-term outcome and prognostic factors. Arch Bronconeumol 2015; 51(2): 61-8.
From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from: